Cardiff Oncology Financial Results
Cardiff Oncology reported Q3 2026 financial results and provided a clinical update on its Phase 2 trial of onvansertib in first-line RAS-mutated mCRC, noting that median PFS has not yet been reached in the 30 mg arm. The company is preparing for a registrational Phase 3 trial expected to start in Q1 2027 and reported a cash position of $68.1 million as of September 30, 2026.
- Term
- Q3 2026
“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms.”
Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology
“Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”
Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology